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Emorragiche e Trombotiche, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy; 3Dipartimento di Scienze
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Key Points
• The heterozygous in cis
mutations R924Q/
A2178S in a 55-year-





fied in the D9D3 and D4
domains; thus, type 2B
VWD can be generated
not only by typical
mutations in the A1
domain.
We observed a 55-year-old Italian man who presented with mucosal and cutaneous
bleeding. Results of his blood analysis showed low levels of von Willebrand factor (VWF)
antigen and VWF activity (both VWF ristocetin cofactor and VWF collagen binding), mild
thrombocytopenia, increased ristocetin-induced platelet aggregation, and a deficiency of
high-molecular-weight multimers, all typical phenotypic hallmarks of type 2B von
Willebrand disease (VWD). The analysis of the VWF gene sequence revealed heterozygous in
cis mutations: (1) c.2771G.A and (2) c.6532G.T substitutions in the exons 21 and 37,
respectively. The first mutation causes the substitution of an Arg residue with a Gln at
position 924, in the D9D3 domain. The secondmutation causes an Ala to Ser substitution at
position 2178 in the D4 domain. The patient’s daughter did not present the same fatherly
mutations but showed only the heterozygous polymorphic c.3379C.T mutation in exon
25 of the VWF gene causing the p.P1127S substitution, inherited from her mother. The
in vitro expression of the heterozygous in cis VWF mutant rVWFWT/rVWF924Q-2178S
confirmed and recapitulated the ex vivo VWF findings. Molecular modeling showed that
these in cis mutations stabilize a partially stretched and open conformation of the VWF
monomer. Transmission electron microscopy and atomic force microscopy showed in the
heterozygous recombinant form rVWFWT/rVWF924Q-2178S a stretched conformation,
forming strings even under static conditions. Thus, the heterozygous in cis mutations
924Q/2178S promote conformational transitions in the VWF molecule, causing a type
2B–like VWD phenotype, despite the absence of typical mutations in the A1 domain
of VWF.
Introduction
von Willebrand factor (VWF) is a large multimeric glycoprotein mediating platelet adhesion to the
damaged vessel wall under conditions of high shear stress.1 The VWF gene, localized on chromosome
12, spans 178 kb and contains 52 exons. It is transcribed into an 8.8-kb messenger RNA, which
encodes a 2813-aa precursor (pre-pro-VWF) consisting of a 22-aa signal peptide, a 741-aa propeptide,
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and a 2050-aa mature subunit.2-4 The VWF mature subunit is
composed of 4 repetitive domains designated A to D and
arranged in the sequence D9-D3-A1-A2-A3-D4-C1-C2-C3-C4-
C5-C6-CK.5 The von Willebrand disease (VWD) is the most
common and largely heterogeneous inherited bleeding disor-
der in humans, characterized by quantitative and/or qualitative
defects of VWF.6 The classification of congenital VWD is based
on both clinical and laboratory findings according to the recom-
mendations of the VWF Scientific Standardization Committee
(VWF-SSC) of the International Society on Thrombosis and
Haemostasis (ISTH).7 Type 2 VWD is characterized by qualitative
VWF abnormalities causing different functional defects.7 In type
2B VWD, gain-of-function missense mutations in the VWF A1
domain favor interaction with both platelet glycoprotein Ib (GpIb)
receptors and ADAMTS-13, with the consequent loss of the high-
and intermediate-molecular-weight multimers.8 Several type 2
VWD forms derive from compound heterozygous mutations that
give rise to complex clinical and laboratory phenotypes.9-12 In
these complex cases, the ISTH VWD classification cannot clearly
distinguish between the pronounced variants of type 1, 2M, and
2A (IIE) VWD, particularly when VWF levels are below 20 U/dL.13
In this study, we analyzed a novel example of a complex genetic
mutation.We report here 2 heterozygous in cismutations (p.R924Q/
p.A2178S) associated with a complex phenotype, whose genetic




The propositus, an Italian man born in 1964, was observed for the
first time in 2015 in our hospital during a clinical visit for severe
bleeding (fall of hemoglobin [Hb] level 5 3 g/dL in 2 days) due to
a colon endoscopic polypectomy performed 3 days before without
any antihemorrhagic prophylaxis. He did not report any family
history of bleeding. Instead, his anamnesis reported a lifelong
history of mild/trivial spontaneous bleeding (epistaxis, repeated
gastrointestinal bleeding, and easy bruising), severe bleeding after
a tonsillectomy at 5 years of age, when his hemorrhagic disorder
was not yet diagnosed. At our center, he showed a bleeding time
(Ivy test) .20 minutes (normal, ,7 minutes). His ISTH Bleeding
Assessment Tool (BAT) score was 7.14 This patient was diagnosed
in 2010 in another hospital as having a type 1 VWD. However,
upon IV infusion of desmopressin, we observed no signifi-
cant elevation of VWF level. In 2017, when a second colon
polypectomy was performed and a diagnosis of type 2 VWD
was established in our center, he successfully received VWF
factor concentrate for the hemostatic challenge. His daughter
did not show any menorrhagia and hemorrhagic disorder, except
for a large hematoma of the thigh, which appeared after trauma of
moderate intensity.
Measurements of VWF-related parameters
VWF antigen (VWF:Ag) and VWF ristocetin cofactor (VWF:RCo)
were measured by chemiluminescence assays (ACL Acustar;
Instrumentation Laboratory, Werfen Group, Milan, Italy).15,16
Factor VIII (FVIII) activity was measured using a chromogenic
assay (Instrumentation Laboratory, Werfen Group). FVIII binding
to immobilized VWF was performed with the commercially available
Asserachrom VWF:VIIIB assay (Stago, Asnières, France).17 A VWF
collagen-binding (VWF:CB) assay was performed using the
Asserachrom VWF:CB assay (Stago, Asnières, France) using
human type III collagen. The presence of anti-VWF antibodies
was investigated first with the Bethesda assay using the Acustar
VWF:RCo and thereafter confirmed with a previously detailed
enzyme-linked immunosorbent assay method.18 VWF propeptide
(VWFpp) was measured by an enzyme-linked immunosorbent
assay (Sanquin, Amsterdam, The Netherlands), as previously
detailed.19 The activity of ADAMTS-13 was measured by
a fluorescence resonance energy transfer assay, as previously
described.20
Electrophoresis of VWF multimers
The VWF multimer pattern (VWFm) was studied under low- (0.8% to
1.5% agarose) and high-resolution (0.8% to 2.5% agarose)
conditions with sodium dodecyl sulfate (SDS)–agarose gel electro-
phoresis, as previously reported.21
Platelet-aggregation studies
Platelet-aggregation studies were performed with an AggRAM
platelet aggregometer (Helena Biosciences) using 2 to 10 mM
adenosine 59-diphosphate, 10 mg/mL collagen, and 0.3 to
1.2 mg/mL ristocetin (Helena Biosciences). The platelet-aggregation
assays were performed using both plasma of the patients and
the recombinant forms of VWF, used in all cases at a concen-
tration of 2 mg/mL. Mixing tests in aggregometry assays was
also carried out to exclude platelet-type VWD. Thus, gel-filtered
platelets from both the patient and 5 healthy subjects were
tested in crossover aggregometry assays with both normal
platelet-poor plasma (PPP) obtained from the healthy subjects and
with PPP from the patient.22 The ristocetin-induced aggregation by
the recombinant VWF forms was tested using gel-filtered platelets
from healthy donors.
DDAVP test
IV infusions of 1-desamino-8-D-arginine vasopressin (DDAVP; 0.3
mg/kg body weight, diluted in 100 mL of saline) were administered
under medical supervision. Blood was withdrawn for VWF/FVIII
analysis and cell blood count at baseline and 2 hours after the
infusion ended.
Molecular genetics
Molecular genetic analysis of the VWF gene was performed for the
propositus, his daughter, and his wife. Informed consent for the
study was obtained according to the Declaration of Helsinki.
Unfortunately, we could not collect blood from the patient’s parents,
as they were deceased. The paternity test was performed with
the Power-Plex-16 kit (Promega Corp, Madison, WI) following the
manufacturer’s instructions. Analysis of the polymerase chain
reaction products (3 mL) was carried out with the an 3100-Avant
Genetic Analyzer (Applied Biosystems, Foster City, CA). The quality
control followed the proficiency testing of International Society for
Forensic Genetics Working Group (ISFG-WG) guidelines.23
Genomic DNA was isolated from peripheral blood leukocytes using
the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). Sanger-
sequencing procedures were carried out to validate the identified
genetic variants. The specific primer sets were designed using the
Primer3 algorithm (http://frodo.wi.mit.edu/primer3). Other experi-
mental details are provided in supplemental Materials.
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Expression and purification of recombinant WT and
mutated forms of VWF
Expression vectors. The recombinant pSVH expression plas-
mid containing full-length complementary DNA (cDNA) encoding
wild-type (WT) human VWF (pSVHVWFwt) has been described
previously.24 The VWF cassette enclosed by SacI restriction sites
was subcloned into the pCMV6 expression plasmid (pCMV6-
SacIwt) to be further modified. VWFwt cDNA, obtained by restriction
of pSVHVWFwt with EcoRI, was cloned into the pcDNA3 expression
vector to generate the pcDNA3-VWFwt plasmid. Mutation R924Q
was introduced into pSVHVWFwt plasmid with the QuickChange
II XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa
Clara, CA) and the resulting mutated cDNA was verified by
Sanger sequencing and cloned with EcoRI into pcDNA3 to obtain
the pcDNA3-VWFR924Q vector. Mutation A2178S was in-
troduced into pCMV6-SacIwt by site-directed mutagenesis. The
resulting mutated cassette was sequenced and subcloned with
SacI into pSVHVWFwt or pSVHVWFR924Q plasmids. Finally,
these mutated cDNAs were cloned with EcoRI into pcDNA3 to
generate pcDNA3-VWFA2178S and pcDNA3-VWFR924Q/
A2178S, respectively.
Cell culture. HEK293T cells were grown under sterile con-
ditions and adherence in flasks containing Dulbecco modified Eagle
medium supplemented with 10% fetal bovine serum, 4 mM L-glu-
tamine, 125 IU/mL penicillin-G, and 125 ug/mL streptomycin. The
cell culture was maintained at 37°C and 5% CO2.
Transfection. HEK293T cells were transiently transfected
using Lipofectamine 2000 (Invitrogen/Thermo Fisher Scientific,
Waltham, MA) according to the manufacturer’s instructions.
Briefly, cells in a T75 flask at 80% of confluency were transfected
in OptiMEM (Gibco/Thermo Fisher Scientific) with 12 mg of plasmid
DNA. The medium was harvested 48 hours after transfection. With
this procedure, the following constructs were produced: rVWFWT,
heterozygous in cis mutant rVWFWT/rVWF924Q-2178S, homo-
zygous rVWF924Q-2178S, heterozygous rVWFWT/rVWF2178S,
and homozygous rVWF2178S.
Purification of recombinant VWF variants. Phenylmethylsulfonyl
fluoride (100 mM) was added to collected media, which were
centrifuged at 5000g for 5 minutes at 4°C and dialyzed against
N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid (HEPES)
buffered saline overnight at 4°C. VWF variants were then
purified by size-exclusion fast protein liquid chromatography
(ÄKTA Pure Protein Purification System; GE Healthcare/Life
Sciences), using a HiPrep 16/60 Sephacryl S-500 HR column
(GE Healthcare/Life Sciences). The purified protein was
aliquoted and rapidly stored at 280°C
Structural analysis of the missense
VWFp.R924Q-A2178S mutant using
molecular modeling
The heterozygous in cis missense mutations p.R924Q and
p.A2178S identified in this VWF molecule are in 2 domains,
whose crystal-based structures have only partly been resolved.
X-ray crystal structures deposited in the Protein Data Bank
(PDB) site are the D9D3 (S764-L1243), A1 (D1261-1468), A2
(M1495-H1674), and A3 domains (D1685-S1873) (PDB file
identifiers “6N29,” “1AUQ,” “3GXB,” and “1ATZ,” respectively).
Thus, we decided to perform molecular modeling of the VWF
sequence S764-V2191 using the I-TASSER threading model-
ing server (Iterative ThreadingASSEmbly Refinement) (http://
zhanglab.ccmb.med.umich.edu/I-TASSER/).25,26
TEM analysis
Samples for transmission electron microscopy (TEM) were
prepared by dialyzing for 24 hours at 4°C VWF variants for
purification in 20 mM HEPES, 150 nM NaCl, pH 7.40. Proteins
were concentrated up to 25 ng/mL. Salt crystals in the samples
were eliminated with Zeba Desalt Spin Columns (Thermo Scientific).
Subsequently, a small drop (10 mL) was dispersed on carbon-coated
glow-discharged copper grids and stained with a small drop of 2%
uranyl acetate before dehydration.
Atomic force microscopy
Atomic force microscopy (AFM) imaging was performed using
a NanoWizard II (JPK Instruments, Berlin, Germany) in the contact
operation mode. All samples were kept in an aqueous environment
and at a controlled temperature (25°C) throughout the measure-
ment procedure, as detailed elsewhere.27 This approach was aimed
at minimizing perturbations and artifacts due to salt crystallization
following dehydration that could hide or modify the real particle
structure.28






Gene mutations Het. in cis mutations
c.2771G.A (exon 21) 1
c.6532G.T (exon 37)
INR 0.95 — 0.8-1.2
aPTT, s 45.4 44.3 22-38
Fibrinogen, mg/dL 349 338 200-400
VWF:Ag, IU/dL 23.4 29 50-150
VWF:RCo, IU/dL 8.5 10 50-150
VWF:CBA, IU/dL 7.2 8 50-150
FVIII:C, IU/dL 28.2 33 50-150
VWFpp, % 63.4 — 50-120
VWF:RCo/VWF:Ag 0.36 0.34 0.75-1.25
VWF:CBA/VWF:Ag 0.31 0.28 0.75-1.2
VWFpp/VWF:Ag 2.7 — 0.75-1.25
FVIII/VWF:Ag 1.2 1.14 0.75-1.25
FVIII/VWF:binding, % 127.8 — 70-130
ADAMTS-13 act, U/dL 110.1 — 70-130
Platelets, 3109/L 121-166 85 200-400
Hb, g/dL 8.1-15.1 — 12.5-15




—, the measurement of the corresponding parameter was not performed; ADAMTS-13
act, ADAMTS-13 activity; aPTT, activated partial thromboplastin time; CBA, collagen-
binding assay; FVIII:C, FVIII coagulant; Het., heterozygous; INR, international
normalized ratio.
*Blood group of the daughter: A-Rh 1 - Rh phenotype: CcDee-Kell/Cellano: kk.














The patient had a moderate reduction of VWF:Ag plasma levels,
and a more pronounced reduction of VWF activity and VWF:CB
plasma levels as listed in Table 1. As a consequence, the relative
VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag ratio values were
markedly reduced. Anti-VWF antibodies were absent. These
findings agreed with the multimer VWF analysis that showed
a severe absence of both high- and intermediate-molecular-
weight multimers (defined as the cumulative bands above the
10th band and between the seventh and 10th bands, re-
spectively) as shown in Figure 1A. Moreover, the analysis of the
high-resolution SDS–agarose gel electrophoresis showed an
accumulation of small multimers and a stronger representation
of the satellite bands of each oligomer (Figure 1B). SDS–
polyacrylamide gel electrophoresis (PAGE) of the reduced
VWF samples from the propositus showed, compared with normal
plasma, increased representation of the 170- and 140-kDa bands,
which are the products of the ADAMTS-13 activity (Figure 1C). The
FVIII:C level was found proportional to the VWF:Ag level, resulting
in an FVIII/VWF ratio of 1.2. FVIII-binding assays performed on
plasma samples from the propositus demonstrated normal values,
as shown in Table 1. We next explored whether the decreased
VWF:RCo/VWF:Ag ratio of the propositus could be associated
with accelerated peripheral clearance of high-molecular-weight
multimers. To address this point, we measured plasma levels of
VWFpp.19 In the patient, the VWFpp/VWF:Ag ratio results were
abnormally increased, being equal to 2.7 (normal median value,
0.85 [interquartile range, 0.75-1.25] in 10 healthy controls).
Characterization of genetic mutation
The analysis of the propositus’ VWF gene sequence revealed 2 in
cis heterozygous mutations: (1) the c.2771G.A substitution in
exon 21 and (2) the c.6532G.T substitution in exon 37. The
c.2771G.A change causes the substitution of an arginine residue
with glutamine at position 924 (p.R924Q), in the D9D3 domain of
the mature protein. Arg924 is implicated in the interaction with
FVIII.29 Although the effect of this mutation is highly debated in the
literature,30 some functional studies also indicate a capacity of
the variant to alter VWF levels.29,31 The variant is reported in the
dbSNP database (http://www.ncbi.nlm.nih.gov/snp/), rs33978901,
with a minor allele frequency in the European population ranging
between 0.01 and 0.02, or in other studies as a polymorphic variant.










Figure 1. SDS-agarose and SDS-PAGE of VWF
multimers. (A) SDS–agarose electrophoresis gels of
VWFm in the patient, his wife, and daughter. The bands
were detected with a ChemiDoc densitometer (Bio-Rad).
(B) Discontinuous high-resolution (0.8% to 2.5%) SDS-
agarose gel electrophoresis of VWFm from the same
plasma sample. (C) Western blots of VWF samples of the
patient reduced with phosphine (Bio-Rad) in precast
SDS-PAGE (4% to 12%) gel using a Criterion apparatus
(Bio-Rad).The arrows indicate VWF bands produced by
the ADAMTS-13 proteolysis. NP, normal plasma.
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32,33 The genetic variant c.6532G. T identified in exon 37 of the
VWF gene causes the replacement of the alanine at position 2178
with a serine (p.A2178S). The variant is reported in the dbSNP
database (http://www.ncbi.nlm.nih.gov/snp/), rs34230288, with
a minor allele frequency in the European population of 0.02. This
variant is tolerated in all of the in silico systems used. Unexpectedly,
none of these mutations were found in his daughter. Thus,
a paternity test was mandatory; the true paternity was confirmed
with a Combined Paternity Index (CPI).2993 106 and a paternity
probability .99.99999%. The VWF genetic profiles of the patient,
his daughter, and his wife as well as the result of the paternity test
allowed us to conclude that the patient was affected by 2
heterozygous in cis mutations: p.R924Q/p.A2178S (Table 1).
Expression of recombinant VWF constructs
All of the recombinant VWF variants (rVWFWT, rVWFWT/rVWF
924Q-2178S, homozygous rVWF924Q-2178S, heterozygous
rVWFWT/rVWF2178S, and homozygous rVWF2178S) were pro-
duced and secreted by HEK293T cells in good amounts and normal
multimeric pattern (supplemental Figure 1).
Platelet aggregation
The platelet aggregation induced by adenosine 59-diphosphate and
collagen was normal (data not shown) but increased response to
low-dose ristocetin was observed. Although the PPP contained
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Figure 2. Ristocetin-induced platelet aggrega-
tion of the patient. (A) Ristocetin-induced platelet
aggregation of the patient and age- and sex-
matched healthy control subject. The concentration
of ristocetin used in each test is indicated; in all
cases, the VWF concentration was 20 IU/dL. (B)
Crossover aggregometry assay using gel-filtered
platelets from normal control (Plt ctrl, 140 000/mL)
in the presence of the patient’s PPP and platelets
from the patient at the same count with PPP from
normal control. The latter was used at the same
VWF concentration present in the patient’s plasma
(2 mg/mL) by diluting it with plasma of a subject
with type 3 VWD. Ristocetin was used at
0.6 mg/mL. (C) Ristocetin-induced aggregation of
gel-filtered platelets from a healthy control subject
tested with the recombinant VWF constructs in-
dicated in the figure. In all cases, the VWF concen-
tration was 20 IU/dL.
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aggregation was observed at low ristocetin concentration
(0.3 mg/mL). In fact, platelet agglutination by 1.2, 0.6, 0.3 mg/mL
ristocetin was equal to 71%, 40%, and 28%, respectively (Figure 2A).
The crossover aggregometry experiments showed that platelets of
the patient had a normal response to 1.2 mg/mL ristocetin but very
low or no aggregation was recorded at 0.6 mg/mL ristocetin in the
presence of PPP from normal subjects. At variance with this result,
platelets from healthy controls showed an abnormally high
aggregation when tested with PPP of the patients at 0.6 mg/dL
ristocetin (Figure 2B). The recombinant WT and mutant VWF
constructs were also tested in aggregometry experiments.
Homozygous rVWF 924Q-2178S showed a maximum aggre-
gation in the presence of 0.3 mg/mL ristocetin comparable to
that elicited by 1.2 mg/mL rVWFWT (Figure 2C). At 0.3 mg/mL
ristocetin, rVWF924Q-2178S showed an @32% maximum aggrega-
tion, whereas for rVWFWT, heterozygous rVWFWT/rVWF2178S,
and homozygous rVWF2178S, aggregation was virtually absent
(Figure 2C). The propositus did not respond to desmopressin.
Indeed, 2 hours after infusion of desmopressin at a dose of 0.3
mg/kg body weight, he showed a very modest increase of VWF:
Ag, VWF:RCo, and FVIII (Table 1), with transient thrombocyto-
penia (platelet count pre-DDAVP 1593 109/L, post-DDAVP 853
109/L), associated with the formation of platelet clumps 2 hours
after the infusion (data not shown).
ADAMTS-13 level and proteolyzed VWF fragments
Plasma ADAMTS-13 activity level values for the patient, as listed in
Table 1, were normal. Hence, the increased presence of the
proteolyzed VWF bands in the propositus’ plasma (Figure 1C) was
not produced by the enhanced activity of the enzyme but, rather, by
a different susceptibility of VWF to the ADAMTS-13 activity.
Molecular modeling of the missense mutations
p.R924Q and p.A2178S
I-TASSER was used to generate structure predictions for both the
WT VWF monomer (sequence 764-2191) and the mutant bearing
the point mutations p.R924Q and p.A2178S (Figure 3). The mean
estimated template model (TM) and root-mean-square deviation
(RMSD) score, calculated for the statistically best models, were
equal to 0.94 and 3.85 Å, respectively, for the WT VWF form and
0.93 and 4.64 Å, respectively, for the heterozygous rVWFWT/
rVWF 924Q-2178S form. These modeling results are largely
consistent with the good results from the I-TASSER modeling in the
previously reported Critical Assessment of Structure Prediction
(CASP) experiments.34,35 The ResQ program uses algorithms to
predict the TM score and RMSD of the model relative to its native
structure based on the predicted local distances, with the
corresponding TM score and RMSD formula.36 Estimated local
quality and B factor for the residues of the WT and double mutant
VWF constructs are reported in supplemental Tables 1 and 2.
Notably, the change of polarity and charge of the 2 missense
mutations caused a major conformational change in the global
structure of the mutant compared with the WT monomer, as shown
in Figure 3. The substitution of Arg924 with a Gln residue, for
instance, causes a loss of several polar contacts between the
side-chain atoms of Arg924 and Gly913, His916, and Lys843
(Figure 4A). The absence of these polar interactions likely
contributes to partial opening of the compact assembly of b5-
b12 strands in the D3 domain, as predicted by the modeling shown
in Figure 3. Likewise, the polarity change due to the presence of the
hydroxyl residue of S2178 causes a partial distortion of the a4 helix
in the D4 domain (Figure 4B-C).
TEM
Electron micrographs of both rVWFWT and the heterozygous
rVWFWT/rVWF 924Q-2178S are shown in Figure 5A-B. A
significant difference was observed in the conformation of the
WT and the mutant. The WT form was observed in a compact/
globular configuration like a “ball of yarn” (Figure 5A), whereas the
heterozygous rVWFWT/rVWF 924Q-2178S mutant was mainly
present as fully extended bundles, occasionally approaching
a length of 1000 nm but usually being ,500 nm long and forming
pieces of a net due to strings crossing (Figure 5B). In the TEM
images, the fully folded conformers showed a diameter of the major
axis ranging from 3 to 20 nm.
AFM
The images obtained with AFM under static conditions showed
structural patterns of both the rVWFWT and the heterozygous
rVWFWT/rVWF924Q-2178S constructs very similar to that
obtained with TEM (Figure 5C-D). This is particularly relevant
because in the TEM experiments, samples were dry; in the AFM
experiments, the samples were hydrated. Despite the different







Figure 3. Prediction of the molecular structure. Prediction of the molecular
structure of the VWF sequence 764-2191 for both the WT (A) and the double
mutant p.R924Q and p.A2178S (B). Model joining was performed by constraining
the intrachain disulfide bonds previously assigned with x-ray diffraction and bio-
chemical studies.5 The accuracy of the generated models was assessed with the
ResQ program,36 which checks the residue-specific local quality of the I-TASSER
models. The ResQ algorithm analyzed and assessed the validity of several parame-
ters: (a) the structural variations of Monte Carlo assembly simulations, (b) distance
deviations of the templates detected by threading and structural alignment, (c) the
threading alignment coverage, and (d) the consistency between the model and the
sequence-based predictions of structural features. All structural analysis and image
rendering were performed with the Pymol software (v. 2.3.3). The 2 models are
shown in the same orientation. I-Tasser and ResQ were used to generate the mod-
els. R924, Q924, A2178, and S2178 are shown in red sticks. Pymol software was
used to view and manipulate the generated PDB file.
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rVWFWT/rVWF 924Q-2178S construct were observed in the AFM
analysis with similar dimensions (Figure 5C-D). In the mutant form,
the AFM technique allowed a 3-dimensional (3D) analysis revealing
a bundle height of ;27 nm (Figure 5D). This finding is likely
explainable with overlapping strings forming a net through pro-
cesses of molecular interstring aggregation. Furthermore, AFM
was used in force-measuring experiments on a single molecule
(Figure 6). In a typical stretching experiment, the force-extension
curve shows a saw-tooth pattern, each peak corresponding to the
unfolding of a single domain of the protein. The force-extension
profile of a polymeric molecule like VWF is complex and cannot be
fully interpreted.37 However, the height of each force peak reflects
the energetics of the mechanical stability of a protein’s domain,
whereas the distance between peaks measures the length of the
protein region that is unfolded.38 Figure 6A-B shows that the global
profile and the peak height of the mutant VWF are very different
(Figure 6B) from those of the WT form (Figure 6A). The saw-tooth
pattern observed in the WT form, although having complex
asymmetry characteristics, was almost completely lost in the mutant
VWF. Moreover, the WT form has a median unfolding force of ;17
pN (Figure 6C), whereas the heterozygous rVWFWT/rVWF 924Q-
2178S has an average unfolding force of ;7 pN (Figure 6D).
Discussion
We report here the first case of a type 2B VWD patient carrying
mutations at the D9D3 and D4 VWF domains. From a simply
phenotypic standpoint, we could assign this case to a canonical
type 2B VWD, associated with gain-of-function missense mutations
over the region comprising the amino acid 1266-1461 in the A1
domain of the VWF molecule.21,39 The gain-of-function mutations in
the type 2BVWD arise from the capacity of these VWF mutants to
undergo an easier conformational transition under low shear forces
from a globular to a stretched conformation. This change permits
the interaction with platelet GpIb and ADAMTS-13.21,40-43 The
enhanced VWF-induced platelet aggregation causes their con-
sumption, and accelerated proteolysis by ADAMTS-13 contributes
to the loss of the high- and intermediate-molecular-weight multi-
mers, as usually observed in type 2B VWD. This is in conformity with
results obtained from electrophoretic studies of VWF multimers
(Figure 1A-B) and the increase of the VWFpp/VWF:Ag ratio
observed in our propositus. Based on phenotypic and laboratory
findings of the propositus, we expected to find mutations in the
VWF A1 domain to confirm a canonical type 2B VWD diagnosis.
At variance with this hypothesis, we found heterozygous in cis
mutations within the D9D3 and D4 domains. The former is usually
invoked as the site of mutations responsible for the reduced VWF
interaction with FVIII, found in the type 2N VWD.44 However, in the
propositus, the value of the FVIII/VWF ratio and the measured FVIII-
VWF interaction were normal. Both TEM and AFM experiments
clearly showed that, even under static conditions, the compound
heterozygous VWF form is mainly composed of stretched con-









Figure 4. Details of the model of WT VWF and heterozygous in cis p.R924Q/p.A2178S (sequence Ser764-Val2191) obtained with the I-Tasser program. (A)
Hydrogen bonds between the side chain of R924 with the side chains of surrounding residues in WT form. These bonds are completely lost in the heterozygous in cis mutant.
The figure, prepared with the PyMol software, shows the polar interactions (dashed lines in yellow) of the side chain of Arg924 with surrounding amino acids. Structure of the
a4 chain of the D4 domain (H2169-A2181 in the red cartoon with the side chain of A2178 in yellow sticks) of the WT VWF form (B) and in the heterozygous in cis p.R924Q/
p.A2178S mutant (H2169-A2181 in the red cartoon with the side chain of S2178 in yellow sticks) (C). To assess the putative structural effect of the in cis heterozygous
p.R924Q/p.A2178S mutations over the entire region from Ser764 to Val2191, also comprising part of the D4 domain (V1875-V2191),5 we modeled this region on the
I-TASSER threading modeling server (Iterative Threading ASSEmbly Refinement; http://zhanglab.ccmb.med.umich.edu/I-TASSER/).25,26
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facilitated interaction with the platelet GpIb and ADAMTS-13.
Altogether, these molecular abnormalities, although not involving
mutations in the A1 domain, greatly resemble the laboratory findings
of a canonical form of a type 2B VWD. Based on this scenario, the
question arises regarding which mechanism is responsible for this
apparently contradictory situation. We believe that the unexpected
or apparent mismatches between the phenotypic manifestations
and the localization of genetic mutations, observed in this case,
stem from the structure and conformational equilibria, to which the
VWF multimers are strongly subjected.45-47 In this case, an early
step of the VWF molecule maturation process, that is the
dimerization, may be specifically affected by the heterozygous in
cis mutations described herein. At the acidic pH present in the
Golgi apparatus and Weibel-Palade bodies, the C terminus of
@1350 aa of VWF zip up into an elongated conformer, resembling
a dimeric bouquet, ;63 nm long.48 The formation of this bouquet
engages a rigid stem, the D4-C1-C2 domains, and a more flexible
petal-like terminus, composed of the D9D3-A1-A2-A3 domains.48 In
the molecular “bouquet,” the interaction between the coupled D4
domains of 2 different monomers drives their approach, facilitating
the formation of disulfide bonds through cysteines in the CK
domains. Thereafter, hydrogen and apolar bonds between the C1
and C2 domains reinforce the formation of the dimeric bouquet. In
circulation at physiological pH of 7.4, shear forces of @50 pN can
dissociate the stem of the dimeric bouquet.48,49 However, the 2
parts of the bouquet are still covalently connected through
cysteines so that the dimer roughly doubles its length and allows
VWF multimer stretching. During this conformational transition, the
D9D3 domain, which shields the A1 domain under static conditions,
undergoes a structural change, exposing the GpIba-binding site in
the A1 domain and the Y1605-M1606 peptide bond proteolyzed by
ADAMTS-13 in the A2 domain.48 Noticeably, an anti-VWF
monoclonal antibody (1C1E7) that recognizes an epitope in the
764- to 1035-aa region at the N-terminal D9D3 domains enhances
VWF/GPIba binding, proving that the D9D3 region of VWF
negatively modulates VWF/GPIb-IX-V interaction50 under static
conditions. Hence, it is likely that the drastic changes of polarity and
charge associated with the p.R924Q and p.A2178S mutations in
cis may cooperatively alter the early steps of the conformational
changes described earlier in this paragraph. The steric and polarity
changes caused by these mutations, as shown by the results
obtained by molecular modeling, favor the transition to a stretched
conformation of VWF at shear forces lower than those needed for
the WT VWF molecule, as previously observed in a canonical type
2B VWD.21 The use of TEM and AFM techniques has shown that
the heterozygous in cismutations can indeed promote the transition
toward an open/stretched conformational state of the VWF variant
even in the virtual absence of shear forces. Likewise, lower than
expected concentrations of ristocetin, whose binding to the A1
domain of VWF causes the same functional effects of mechanical
forces,49,51-53 were demonstrated to favor the interaction of the
VWF variant to the platelet receptor, causing transient thrombocy-
topenia. In canonical forms of type 2B VWD, thrombocytopenia can
be only transiently present and therefore sometimes not identified
among the diagnostic criteria of type 2B VWD. In the pathological
analysis of the propositus, thrombocytopenia was inconstant and
mainly associated with stressful conditions, infections, and surgery,
as previously reported in type 2B VWD.8 In conclusion, this form of
VWD differs from the canonical type 2B VWD forms as to the
localization of causative genetic mutations, present in cis in the
D9D3 and D4 domains. This scenario could suggest the existence
of a novel subtype of 2B VWD that could be defined as type 2BD3D4
. The results of this study show how genetic mutations occurring in












Figure 5. TEM analysis. TEM analysis of both the recombinant
rVWFWT (A) and heterozygous in cis rVWFWT/rVWF924Q-
2178S form (B) and images obtained with AFM of the recombi-
nant WT (C) and mutant (D) VWF form. (A-B) The sample could
adsorb on the carbon film for 5 minutes, and the sample excess
was removed with filter paper. After staining with a 2% uranyl
acetate solution for 30 seconds in the dark at room temperature,
staining excess was also removed with filter paper and the grid
washed with ultrapure water. Grids were then air-dried for 1 hour
before observation at room temperature. TEM micrographs were
collected, working with an acceleration voltage of 120 keV at
a magnification of 330 000 (Libra 120; Carl Zeiss Meditec, Jena,
Germany). Notably, a great difference in the conformational state
between the 2 forms can be observed. Even in the absence of
shear stress, the conformation is globular for the WT VWF,
whereas it is mainly unfolded for the mutant, which forms strains
interacting each other. The samples were dry in the TEM method
(tungsten-coated, brightfield-imaged), whereas they were (C-D)
fully hydrated in the AFM experiment.
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of mature VWF multimers, causing the expression of a 2B-like VWD
phenotype. The rapid evolution of genetic and biochemical/biophysical
techniques together with the development of new treatments may
significantly change diagnostic flowcharts for VWD and their use for
specific and personalized treatment.
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Figure 6. Force-extension assay of recombinant VWF forms using AFM. (A) The force-extension curve shows a saw-tooth pattern54 for the WT form. (B) The heterozy-
gous in cis mutant shows a much flatter profile. The microscope probe consisted of an ultrasharp silicon nitride cantilever of nominal force constant k 5 0.1 N/m, with a tip
radius of ,10 nm (MikroMasch NSC16; NanoWorld, Neuchâtel, Switzerland). Image analysis was performed using Gwyddion software (Czech Metrology Institute, Brno,
Czech Republic). (B) The force-extension curve concerning the in cis heterozygous form shows constant force plateaus, which are the expression of the mechanical unzipping
of linear interactions between multiple linear polymer chains.55 (C) Statistical analysis of the experimental data showed that the WT form has a median unfolding force of ;17
pN in good agreement with the average VWF unfolding force value previously reported.21 (D) The in cis heterozygous form has an average unfolding force of ;7 pN. These
unfolding force profiles agree with the morphological counterparts (Figure 5).
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